<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04991961</url>
  </required_header>
  <id_info>
    <org_study_id>HASA-China2020</org_study_id>
    <nct_id>NCT04991961</nct_id>
  </id_info>
  <brief_title>Effect of Anti-hypertensive Medications on the Diagnostic Accuracy in Screening for Primary Aldosteronism</brief_title>
  <acronym>HASA</acronym>
  <official_title>Effect of Anti-hypertensive Medications on the Diagnostic Accuracy in Screening for Primary Aldosteronism：a Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chongqing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effect of anti-hypertensive medication on efficiency of primary aldosteronism&#xD;
      screening test, and to determine the appropriate diagnostic cutoff valuefor Chinese&#xD;
      hypertension patients during antihypertensive drugs therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aldosterone-Renin ratio (ARR)is currently the most reliable means available for screening for&#xD;
      primary aldosterone（PA）. However, some antihypertensive drugs may cause false positives and&#xD;
      false negatives on ARR. Thus, America PA guidelines suggest that antihypertensive drugs&#xD;
      should be withdraw or change therapy before screening.&#xD;
&#xD;
      But withdraw/changing the therapy before ARR is inconvenient for patients.&#xD;
&#xD;
      we prepare to start a prospective study through recruiting hypertension patients who needs&#xD;
      ARR screening test, completing the ARR screening before and after withdraw/change therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmation</measure>
    <time_frame>2 weeks</time_frame>
    <description>Consistent diagnosis after drug withdrawal</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Missing Diagnosis</measure>
    <time_frame>2 weeks</time_frame>
    <description>essential hypertension turn to fit primary aldosteronism diagnosis after drug withdrawal</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Misdiagnosis</measure>
    <time_frame>2 weeks</time_frame>
    <description>primary aldosteronism turn to fit essential hypertension diagnosis after drug withdrawal.</description>
  </primary_outcome>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Hypertension</condition>
  <condition>Primary Aldosteronism</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>withdraw antihypertensive drugs</intervention_name>
    <description>patients need to withdraw of all antihypertensive drugs or change therapy to Doxazosin/Diltiazem for 2-4 weeks prior</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients in the Department of Endocrinology and physical examination center of First&#xD;
        Affiliated Hospital of CQMU who with hypertension, and under anti-hypertension medication&#xD;
        therapy and being certificated with high risk factors of PA were recruited as the study&#xD;
        group.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Persistent hypertension &gt;150/100mmHg, including previously diagnosed grade 2&#xD;
             hypertension but well controlled by 1-2 drugs; newly diagnosed hypertension with 3&#xD;
             days blood pressure &gt; 150 / 100mmHg&#xD;
&#xD;
          -  Resistant hypertention(combined with three antihypertensive drugs and one of them is&#xD;
             diuretic but blood pressure is still greater than 140 / 90 mmHg ; or need to combined&#xD;
             four anti-hypertensive drugs to control the blood pressure under 140 / 90 mmHg)&#xD;
&#xD;
          -  Family history of hypertension with early onset (&lt; 40 years old)&#xD;
&#xD;
          -  Family history of hypertension with early onset (&lt;40 years old) and cerebrovascular&#xD;
             accident&#xD;
&#xD;
          -  Hypertension with spontaneous or diuretic hypokalemia&#xD;
&#xD;
          -  Hypertensive with adrenal incidentaloma&#xD;
&#xD;
          -  Hypertensive with OSAS&#xD;
&#xD;
          -  First-degree relatives of PA patients and with hypertension Stable antihypertensive&#xD;
             medication therapy for more than 2 weeks, medication including：β-blockers, CCB, ACEi,&#xD;
             ARB, MRA, and other diuretics.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients hard to change or stop the medication for accomplish the screening test or&#xD;
             diagnosis Unwilling to participate the study and refuse to sign on informed consent&#xD;
             Patients who was diagnosed with other secondary hypertension Suspected with PA（rein&#xD;
             concretion beyond the limit of normal reference range after stoping or changing the&#xD;
             medication） Severe renal insufficiency （eGFR&lt;30 ml/min/1.73m2）; pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Qifu, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>First Affiliated Hospital of Chongqing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li Qifu, PhD</last_name>
    <phone>+86-023-89011552</phone>
    <email>liqifu@yeah.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yang Shuming, PhD</last_name>
    <phone>+86-023-89011552</phone>
    <email>443068494@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Qifu Li</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qifu Li, PhD</last_name>
      <phone>+86 23 89011552</phone>
      <email>liqifu@yeah.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shumin Yang, PhD</last_name>
      <phone>02389011552</phone>
      <email>443068494@qq.com</email>
    </contact>
    <investigator>
      <last_name>Shumin Yang, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qingfeng Cheng, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jinbo Hu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yue Wang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qifu Li, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhihong Wang, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jian Long, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Viola A, Monticone S, Burrello J, Buffolo F, Lucchiari M, Rabbia F, Williams TA, Veglio F, Mengozzi G, Mulatero P. Renin and aldosterone measurements in the management of arterial hypertension. Horm Metab Res. 2015 Jun;47(6):418-26. doi: 10.1055/s-0035-1548868. Epub 2015 May 8. Review.</citation>
    <PMID>25993253</PMID>
  </reference>
  <reference>
    <citation>Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young WF Jr. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016 May;101(5):1889-916. doi: 10.1210/jc.2015-4061. Epub 2016 Mar 2.</citation>
    <PMID>26934393</PMID>
  </reference>
  <reference>
    <citation>Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis. 2001 Apr;37(4):699-705.</citation>
    <PMID>11273868</PMID>
  </reference>
  <reference>
    <citation>Niizuma S, Nakahama H, Kamide K, Fukuchi K, Iwanaga Y, Nakata H, Yoshihara F, Horio T, Nakamura S, Kawano Y. The cutoff value of aldosterone-to-renin ratio for the diagnosis of primary aldosteronism in patients taking antihypertensive medicine. Clin Exp Hypertens. 2008 Oct;30(7):640-7. doi: 10.1080/10641960802443282.</citation>
    <PMID>18855267</PMID>
  </reference>
  <reference>
    <citation>Young WF Jr. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med. 2019 Feb;285(2):126-148. doi: 10.1111/joim.12831. Epub 2018 Sep 25. Review.</citation>
    <PMID>30255616</PMID>
  </reference>
  <results_reference>
    <citation>Schwartz GL, Turner ST. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem. 2005 Feb;51(2):386-94.</citation>
    <PMID>15681560</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 28, 2021</study_first_submitted>
  <study_first_submitted_qc>July 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2021</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chongqing Medical University</investigator_affiliation>
    <investigator_full_name>Qifu Li</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>Aldosterone-Renin ratio</keyword>
  <keyword>Primary aldosteronism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hyperaldosteronism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antihypertensive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

